Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huifeng Niu

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
The American Journal of Pathology|July 11, 2002
Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1Annunziata Gloghini, Gianluca Gaidano, Luigi M Larocca, et al.
Cancer Research Communications|March 27, 2023
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human StudyYasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, et al.
Investigational New Drugs|December 20, 2013
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemiaKevin R Kelly, Thomas C Shea, André Goy, et al.
Molecular Cancer Therapeutics|January 8, 2010
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor modelsSherif Daouti, Brian Higgins, Kenneth Kolinsky, et al.
Cancer Research|February 27, 2009
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapySherif Daouti, Huisheng Wang, Wen-hui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarkerLucy Lee, Huifeng Niu, Ruediger Rueger, et al.
Science Advances|May 22, 2021
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoveryKenichi Iwai, Tadahiro Nambu, Yukie Kashima, et al.
Nature Communications|November 19, 2023
CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockadeTomoko Yamamori Morita, Jie Yu, Yukie Kashima, et al.
Ebiomedicine|November 11, 2017
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase InhibitorHuifeng Niu, Hyunjin Shin, Feng Gao, et al.
Science Advances|May 28, 2019
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitorKenichi Iwai, Tadahiro Nambu, Ryo Dairiki, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The American Journal of Pathology|July 11, 2002
Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1Annunziata Gloghini, Gianluca Gaidano, Luigi M Larocca, et al.
Cancer Research Communications|March 27, 2023
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human StudyYasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, et al.
Investigational New Drugs|December 20, 2013
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemiaKevin R Kelly, Thomas C Shea, André Goy, et al.
Molecular Cancer Therapeutics|January 8, 2010
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor modelsSherif Daouti, Brian Higgins, Kenneth Kolinsky, et al.
Cancer Research|February 27, 2009
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapySherif Daouti, Huisheng Wang, Wen-hui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarkerLucy Lee, Huifeng Niu, Ruediger Rueger, et al.
Science Advances|May 22, 2021
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoveryKenichi Iwai, Tadahiro Nambu, Yukie Kashima, et al.
Nature Communications|November 19, 2023
CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockadeTomoko Yamamori Morita, Jie Yu, Yukie Kashima, et al.
Ebiomedicine|November 11, 2017
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase InhibitorHuifeng Niu, Hyunjin Shin, Feng Gao, et al.
Science Advances|May 28, 2019
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitorKenichi Iwai, Tadahiro Nambu, Ryo Dairiki, et al.
Pageof 3